Vanguard disaggregates holdings; reports 0 shares of Calumet Inc (CLMT)
Rhea-AI Filing Summary
The Vanguard Group filed an amendment to Schedule 13G/A reporting 0 shares of Calumet Inc. The amendment notes an internal realignment on January 12, 2026 and explains that certain subsidiaries/business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The filing is signed on 03/26/2026 and shows no sole or shared voting or dispositive power over Calumet common stock.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Why did Vanguard change how it reports its Calumet Inc holdings (CLMT)?
The filing attributes the change to an internal realignment on January 12, 2026. It says certain subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998).
When was the Schedule 13G/A amendment for CLMT signed and filed?
The signature block shows the form was signed on 03/26/2026, and the amendment is labeled Amendment No. 1 with an internal date of 03/13/2026 referenced at the top of the excerpt.
Who signed the CLMT Schedule 13G/A amendment for Vanguard?
The filing is signed by Ashley Grim, whose title is listed as Head of Global Fund Administration. The signature date is shown as 03/26/2026.
Does the filing identify any third party with rights to dividends or sale proceeds for CLMT?
The filing states that The Vanguard Group, including managed accounts, have the right to receive or direct receipt of dividends or proceeds for the securities reported, but it also states no other person's interest reported exceeds 5% of the class.